From: Gene-expression signature functional annotation of breast cancer tumours in function of age
Patients’ group (years and [n]) | n 1413 | ≤40 (n = 166) | 40 < x < 70 (n = 974) | ≥70 (n = 273) | p-value | |
---|---|---|---|---|---|---|
Age (years) | Â | Â | Â | Â | Â | Â |
 | Median (IQR) | 57 (47–67) | 36 (33–38) | 56 (49–62) | 74 (72–80) |  |
ER status | Â | Â | Â | Â | Â | Â |
 | Positive | 1054 (76 %) | 90 (55 %) | 735 (76 %) | 229 (85 %) | <0.0001 |
 | Negative | 341 (24 %) | 73 (45 %) | 227 (24 %) | 41 (15 %) |  |
HER2 status | Â | Â | Â | Â | Â | Â |
 | Positive | 85 (23 %) | 25 (36 %) | 46 (19 %) | 14 (22 %) | 0.0407 |
 | Negative | 292 (77 %) | 44 (64 %) | 198 (81 %) | 50 (78 %) |  |
Nodal status | Â | Â | Â | Â | Â | Â |
 | Positive | 498 (36 %) | 62 (38 %) | 319 (33 %) | 117 (46 %) | 0.0263 |
 | Negative | 889 (64 %) | 100 (62 %) | 651 (67 %) | 138 (54 %) |  |
SBR grade | Â | Â | Â | Â | Â | Â |
 | 1 | 254 (19 %) | 12 (8 %) | 182 (20 %) | 60 (24 %) | <0.0001 |
 | 2 | 571 (44 %) | 57 (36 %) | 403 (45 %) | 111 (44 %) |  |
 | 3 | 482 (47 %) | 88 (56 %) | 311 (35 %) | 83 (33 %) |  |
Tumour size | Â | Â | Â | Â | Â | |
 | ≤20 mm | 537 (49 %) | 46 (47 %) | 388 (50 %) | 103 (45 %) | 0.4794 |
 | >20 mm | 567 (51 %) | 52 (53 %) | 390 (50 %) | 125 (55 %) |  |